HealthInvest Partners AB Purchases Shares of 37,223 Option Care Health, Inc. (NASDAQ:OPCH)

HealthInvest Partners AB acquired a new position in shares of Option Care Health, Inc. (NASDAQ:OPCH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 37,223 shares of the company’s stock, valued at approximately $1,254,000. Option Care Health makes up about 1.0% of HealthInvest Partners AB’s investment portfolio, making the stock its 24th biggest holding.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Financial Management Professionals Inc. bought a new stake in Option Care Health in the 3rd quarter valued at $29,000. First Horizon Advisors Inc. acquired a new stake in Option Care Health during the third quarter valued at approximately $37,000. Advisors Asset Management Inc. boosted its stake in Option Care Health by 121.4% in the 1st quarter. Advisors Asset Management Inc. now owns 1,337 shares of the company’s stock valued at $42,000 after buying an additional 733 shares in the last quarter. NewEdge Advisors LLC grew its position in Option Care Health by 1,031.9% in the first quarter. NewEdge Advisors LLC now owns 1,562 shares of the company’s stock valued at $50,000 after acquiring an additional 1,424 shares during the period. Finally, Headlands Technologies LLC raised its stake in Option Care Health by 5,796.7% during the third quarter. Headlands Technologies LLC now owns 1,769 shares of the company’s stock worth $57,000 after acquiring an additional 1,739 shares in the last quarter. 98.05% of the stock is currently owned by institutional investors.

Option Care Health Price Performance

NASDAQ OPCH traded up $0.41 on Tuesday, hitting $31.32. 1,474,545 shares of the company were exchanged, compared to its average volume of 1,199,481. Option Care Health, Inc. has a 1-year low of $24.23 and a 1-year high of $35.74. The firm has a 50 day moving average of $32.37 and a two-hundred day moving average of $31.61. The company has a current ratio of 1.77, a quick ratio of 1.33 and a debt-to-equity ratio of 0.74. The company has a market cap of $5.44 billion, a P/E ratio of 21.56, a P/E/G ratio of 1.73 and a beta of 1.22.

Option Care Health (NASDAQ:OPCH) last released its quarterly earnings results on Thursday, February 22nd. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.29 by $0.03. Option Care Health had a net margin of 6.21% and a return on equity of 18.78%. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the firm earned $0.26 earnings per share. Option Care Health’s revenue was up 9.5% compared to the same quarter last year. On average, equities analysts predict that Option Care Health, Inc. will post 1.13 EPS for the current year.

Insider Buying and Selling

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. bought 35,000 shares of the business’s stock in a transaction on Monday, February 26th. The shares were bought at an average cost of $31.55 per share, for a total transaction of $1,104,250.00. Following the transaction, the director now owns 269,528 shares in the company, valued at approximately $8,503,608.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Jefferies Financial Group lifted their price target on shares of Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a report on Monday, March 4th. Barrington Research lifted their target price on shares of Option Care Health from $35.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, February 23rd.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.